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Background: Relaxin activates peroxisome proliferator-activated receptor  (PPAR) by an unknown PPAR ligand-
independent mechanism.
Results: Expression of PPAR coactivator 1 (PGC1) was increased by relaxin through distinct signaling pathways.
Conclusion: The mechanism for relaxin regulation of PPAR is through increased PGC1 levels.
Significance: Discovery of new targets of relaxin signaling may provide further understanding of its pleiotropic effects.
Relaxin activation of its receptor RXFP1 triggers multiple sig-
naling pathways. Previously, we have shown that relaxin acti-
vates PPAR transcriptional activity in a ligand-independent
manner, but the mechanism for this effect was unknown. In this
study, we examined the signaling pathways of downstream of
RXFP1 leading to PPAR activation. Using cells stably express-
ing RXFP1, we found that relaxin regulation of PPAR activity
requires accumulation of cAMP and subsequent activation of
cAMP-dependent protein kinase (PKA). The activated PKA
subsequently phosphorylated cAMP response element-binding
protein (CREB) at Ser-133 to activate it directly, as well as indi-
rectly through mitogen activated protein kinase p38 MAPK.
Activated CREB was required for relaxin stimulation of PPAR
activity, while there was no evidence for a role of the nitric oxide
or ERK MAPK pathways. Relaxin increased the mRNA and pro-
tein levels of the coactivator protein PGC1, and this effect was
dependent on PKA, and was completely abrogated by a domi-
nant-negative form of CREB. This mechanism was confirmed in
a hepatic stellate cell line stably that endogenously expresses
RXFP1. Reduction of PGC1 levels using siRNA diminished the
regulation of PPAR by relaxin. These results suggest that
relaxin activates the cAMP/PKA and p38 MAPK pathways to
phosphorylate CREB, resulting in increased PGC1 levels. This
provides a mechanism for the ligand-independent activation of
PPAR in response to relaxin.
Relaxin is a polypeptide hormone that belongs to the insulin-
like family of peptides (1, 2). The earliest functions attributed to
relaxin involved pregnancy, due to detection of relaxin in the
circulation during the first trimester in humans, and its involve-
ment in implantation, and additional functions which vary
among species. However, now a number of the relaxin non-
reproductive functions have been elucidated, including regula-
tion of vascular tone, vasodilation, fibrosis prevention, and
reversal, and action as a neuropeptide (1). The first relaxin
receptors identified were the leucine-rich G protein-coupled
receptors 7 and 8 (LGR7 and LGR8),3 later renamed relaxin
family peptide receptor (RXFP) 1 and 2, respectively (3, 4).
Relaxin has higher affinity for RXFP1 as compared with RXFP2
in vitro, but has only been shown to activate RXFP1 in vivo, and
therefore RXFP1 is considered the cognate relaxin receptor (5).
Upon activation, RXFP1 couples to multiple G-proteins includ-
ing Gs, Go, and Gi, to modulate cAMP levels through a complex
mechanism involving phosphatidylinositide 3-kinase (PI3K)
and protein kinase C (5– 8). In addition to increased cAMP
production and activation of cAMP-dependent protein kinase
(PKA), relaxin activation of RXFP1 has been tied to other sig-
naling pathways, including tyrosine kinase, the mitogen-acti-
vated protein kinase ERK1/2, nitric oxide, and glucocorticoid
activation (2, 9 –11). Thus, relaxin has shown diverse and com-
plex signaling. We recently identified another signaling path-
way activated by relaxin, involving peroxisome proliferator-ac-
tivated receptor gamma (PPAR) (12).
The peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear receptor superfamily. To date, three
PPAR isoforms have been identified, including PPAR,
PPAR/, and PPAR (13). The PPARs function as transcrip-
tion factors with their heterodimerization partners the retinoid
X receptors. Upon ligand binding, the DNA binding domains of
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the PPARs recognize discrete PPAR response elements (PPRE)
in target gene promoter regions (14, 15). Collectively, the
PPARs act to regulate glucose and lipid metabolism, insulin
sensitivity, inflammation, adipogenesis, vasculature function,
and tissue remodeling (13). Agonists of PPAR regulate adipo-
genesis and insulin sensitivity, and are widely used clinically as
antidiabetic medications. However, PPAR also has anti-in-
flammatory and antifibrotic effects in several tissues (16 –21).
Many of these effects are similar to those induced by relaxin.
This led us to examine whether PPAR was involved in the
cellular effects of relaxin. We found that relaxin activated
PPAR transcriptional activity and activated PPAR target
genes in fibroblasts expressing RXFP1 (12). More recently, it
was found that relaxin stimulation of brain parenchymal arte-
riole remodeling also involved PPAR activation (22, 23).
Despite these recent advances, a number of issues remain
unclear. The signaling pathways triggered by RXFP1 to activate
PPAR are currently unknown. Furthermore, our studies indi-
cated that in fibroblasts expressing RXFP1, relaxin activated
PPAR through a ligand-independent manner (12), but the
mechanism for this activation is unknown. In this study, we
sought to define signaling pathways downstream of RXFP1
leading to activation of PPAR. Moreover, we have explored
the mechanism for the ligand-dependent activation of PPAR
by relaxin, and have identified the coactivator protein PPAR
coactivator 1 (PGC1) as a major player in this activation.
EXPERIMENTAL PROCEDURES
Cells and Transfections—The HEK-RXFP1 cells are HEK-
293T cells stably expressing RXFP1 described previously (12).
For reporter assays, the HEK-RXFP1 cells were transfected
using Fugene6 (Roche) as described previously (12). The plas-
mids included ACO-PPRE-luc (24) provided by Brian Seed
(Harvard University), PGC1-promoter luciferase reporter
(25) and plasmids encoding PKI and inactive mutant
(PKImut) (26) from Addgene, dominant-negative CREB
(KCREB, Clontech, Mountain View, CA), cAMP response
element reporter pGL4.29 (CRE-luc), and Renilla luciferase
plasmid (pTK-RL) (all from Promega). For cotransfection of
siRNA with reporter plasmids, Dharmafect Duo reagent
(Invitrogen) was used according to the manufacturer’s
instructions. The siRNA used were Silencer Select human
PGC1 (s21395), PKA (s11065), p38-MAPK (s3585), or non-
targeting negative control (Invitrogen).
The LX2 cells are a human hepatic stellate cell line (27), and
were provided by Dr. S. L. Friedman (Mount Sinai School of
Medicine, New York). The LX2 cells were transfected using a
Nucleofector 4D device (Lonza) using reagent S.E. and program
EW-113. The ACO-PPRE-luc and pTK-RL plasmids described
above were found to be unsuitable for the LX2 cells. Therefore,
a new PPRE-luciferase reporter (pGL4 –3xPPRE-luc) was con-
structed. Briefly, a DNA fragment containing three tandem
copies of the PPAR response element (28) was inserted between
the KpnI and HindIII sites of the pGL4.26 vector (Promega)
containing a minimal promoter upstream of the firefly lucifer-
ase gene. The Renilla luciferase plasmid used was an SV40-
driven construct (pGL4.72, Promega).
Cells were treated with purified porcine relaxin (kindly pro-
vided by Dr. O. David Sherwood, University of Illinois at
Urbana-Champaign) as indicated in the figure legends. Relaxin
was used at a concentration of 1 nM, which is in the range suf-
ficient for activation of canonical cAMP-related pathways
through RXFP1 (2). Forskolin, the p38 MAPK inhibitor
PD-169316, the PKA inhibitor H89, the PI3K inhibitor
LY294002, the ERK1/2 inhibitor PD98059, the nitric-oxide syn-
thase inhibitor L-NAME, and pertussis toxin were purchased
from EMD Biochemicals. The cyclic nucleotides Sp-6-Bnz-
cAMPS and Sp-8-pCPT-2-O-Me-cAMPS were from Biolog.
The nitric oxide donors SNAP (S-nitroso-N-acetyl-D,L-penicil-
lamine) and GSNO (S-nitrosoglutathione) were from Sigma.
Reporter Assays—Cells were cotransfected with firefly and
Renilla luciferase reporter plasmids as described above. After
24 h, cells were treated as described for the individual figures,
then assays were performed 48 h after transfection. Activation
of reporter constructs was monitored using the Dual-Glo Lucif-
erase assay (Promega) and measured in a Spectramax M5 plate
reader. The data are expressed as the firefly luciferase activity
normalized to the Renilla luciferase in the same sample.
Quantitative Real-time PCR and Conventional RT-PCR—
Total cellular RNA was extracted using the Purelink RNA Mini
kit (Invitrogen), and treated with RNase-free DNase to remove
genomic DNA. The RNA concentration was measured using
the Ribogreen assay (Invitrogen). A total of 2 g of RNA was
reverse transcribed to cDNA using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Carlsbad, CA)
in a total volume of 20 l. The cDNA was then subjected to
TaqMan real-time PCR. The reaction mixtures were comprised
of 2 l of cDNA (diluted 1:15), 10 l of Taqman universal PCR
master mix, 2.5 l Taqman primer/probe mix in a final volume
of 20 l per reaction. The human gene expression assays
(Applied Biosystems) used were PGC1 (Hs00173304_m1) and
TATA binding protein (TBP) (4333769F). Gene expression was
normalized to the level of TBP within each sample using the
relative CT method. Gene expression is shown as relative
expression to control. The data shown are representative of
three independent experiments. For conventional RT-PCR
analysis, total RNA was extracted and cDNA prepared as above
from HEK-RXFP1, THP1, HepG2, and LX2 cells. Expression of
RXFP1 was determined using intron-spanning primers for
human RXFP1 (sense 5-TCTTGGTATTAATTTGGCCGC-
3, antisense 5-CATTAACTCAGGTGGCATCTCC-3, or
GAPDH (sense 5-ACCACAGTCCATGCCATCAC-3, anti-
sense 5-TCCACCACCCTGTTGCTGTA-3) as a loading
control.
cAMP and PKA Assays—The production of cAMP produc-
tion was measured by treating the cells with the indicated con-
centrations of relaxin in the presence of the phosphodiesterase
inhibitors IBMX (0.5 mM) and Ro20 –1724 (0.1 mM) for 30 min
at room temperature. The level of cAMP was measured using
the cAMP-Glo assay (Promega). The level of PKA activation
was determined using the Pep-Tag assay (Promega) according
to the manufacturer’s instructions.
Western Blots—Cells were treated as described for the indi-
vidual experiments, using mammalian protein extraction rea-
gent (M-PER, Pierce, Thermo Scientific, Rockford, IL) contain-
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ing a protease & phosphatase inhibitor mixture (Pierce). The
lysates were sonicated briefly to rupture the cell and nuclear
membranes. The protein concentration was estimated by the
BCA assay (Pierce), and lysates were heated in SDS loading
buffer at 95 °C for 5 min. The proteins were resolved on 10%
polyacrylamide gels and transferred to PVDF membranes. The
membranes were blocked with Odyssey blocking buffer (Li-
Cor, Lincoln, NE), then incubated with diluted primary anti-
body overnight at 4 °C. The primary antibodies used and their
dilutions were total p38 MAPK (9228, 1:1000), phospho-
p38 MAPK (Thr-180/Tyr-182) (4511, 1:1000), CREB (9104,
1:1000), phospho-CREB (Ser-133) (9198, 1:1000), or PKA
(4282, 1:1000), all from Cell Signaling Technology, Danvers,
MA), PGC1 (101707, 1:500, Cayman Chemical, Ann Arbor,
MI), and GAPDH (MAB374, Millipore, Temecula CA). After a
1-hour incubation with fluorescently tagged secondary a-anti-
bodies (Li-Cor, Lincoln, NE), the membranes were scanned on
an Odyssey infrared scanner (Li-Cor).
Statistical Analysis—Curve-fitting and statistical analysis
was performed using Prism5 software (GraphPad, La Jolla, CA).
Differences were analyzed using one-way or two-way analysis
of variance as appropriate, with the Bonferonni post-test. Data
are expressed as mean  S.E. of at least three independent
determinations as indicated in the figure legends.
RESULTS
Relaxin Activates PKA to Activate PPAR Activity—One major
signaling pathway triggered by relaxin is via induction of cAMP
production and activation of cAMP-activated protein kinase
(PKA). To examine the role of cAMP/PKA in activation of
PPAR, HEK-293 cells stably expressing RXFP1 (HEK-RXFP1
cells) were used. We previously showed that relaxin increased
cAMP production and activation of a PPAR response element
(PPRE) via activation of PPAR in these cells, and that these
responses were dependent on RXFP1 (12). Relaxin also
increased PKA activity in these cells, which was blocked by
treatment with the PKA inhibitor H89 (Fig. 1A). Using a PPRE
reporter, treatment of HEK-RXFP1 cells with either forskolin, a
direct adenylyl cyclase activator, or relaxin, increased transcrip-
tional activity through a PPAR response element (PPRE)
reporter, and in both cases this activity was inhibited by the
PKA inhibitor H89 (Fig. 1B). These data confirm that PKA is
activated in response to relaxin, and that the cAMP/PKA path-
way is involved in activation of PPAR transcriptional activity in
these cells.
Because relaxin activates multiple signaling pathways in cells
expressing RXFP1, a panel of activators and inhibitors of vari-
ous pathways was used to screen for potential mechanisms for
FIGURE 1. The cAMP/PKA pathway activates transcription through a PPRE reporter. A, HEK-RXFP1 cells were pretreated for 30 min in the presence of
indicated concentration of the PKA inhibitor H89, then treated 30 min with 1 nM relaxin, and PKA activity was measured by phosphorylation of a PKA substrate.
B, HEK-RXFP1 cells transfected with PPRE and Renilla luciferase reporters were pretreated 30 min in the absence and presence of H89 (20 M), then treated with
10 M forskolin or 1 nM relaxin for 24 h prior to dual luciferase assay. Data are presented as PPRE luciferase assay relative to control, mean  S.E. *, p  .05; **,
p  .01; ***, p  .001, n  3. C, white bars: HEK-RXFP1 cells transfected with PPRE and Renilla luciferase reporters were treated for 24 h with 10 M forskolin, 100
M Sp-6-Bnz-cAMPS, 10 M Sp-8CPT-cAMPS, 100 M SNAP, or 500 M GSNO, then subject to dual luciferase assay. Black bars: cells were pretreated for 30 min
with 20 M H89, 1 g/ml PTX, 2 M LY294002, 20 M PD169316, 10 M PD98059, or 100 M L-NAME, then stimulated with 1 nM relaxin for 24 h. Data are
presented as luciferase activity relative to control, mean  S.E., n  3. *, p  0.05 compared with untreated control; †, p  0.05 compared with relaxin alone. D,
HEK-RXFP1 cells were cotransfected with plasmids encoding PKI or an inactive PKI mutant (PKImut) and PPRE and Renilla luciferase reporters, then treated with
relaxin as described above, then subject to dual luciferase assay. ***, p  0.001; n  3. E, Western blot showing knockdown of PKA or p38 MAPK after treatment
with siRNA. F, HEK-RXFP1 cells were cotransfected with PKA siRNA or nontargeting control siRNA and PPRE and Renilla luciferase reporters, then treated with
relaxin as described above, then subject to dual luciferase assay. ***, p  0.001, n  3.
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relaxin-induced PPAR activation (Fig. 1C). Both forskolin and
the PKA-specific activator Sp-6-Bnz-cAMPS caused increased
PPRE transcriptional activity, but the exchange protein acti-
vated by cAMP (Epac) activator Sp-8-CPT-cAMPS had no
effect. The relaxin-stimulated PPRE activation was completely
inhibited by H89, and partially inhibited by pertussis toxin and
the PI3K inhibitor LY294002. The ERK1/2 inhibitor PD98059
had no influence on the relaxin effect, but the p38 MAPK inhib-
itor PD169316 partially blocked the effect. The nitric oxide
donors (SNAP and GSNO) did not stimulate transcriptional
activity, and the nitric-oxide synthase inhibitor L-NAME did
not inhibit the ability of relaxin to activate PPAR, suggesting
that the nitric oxide is not a mediator of the relaxin effects.
p38 MAPK Is a Downstream Mediator of PKA-induced PPAR
Activity—Because the p38 MAPK inhibitor reduced the relaxin
effect (Fig. 1C), this pathway was studied in more detail. The
p38 MAPK inhibitor caused a partial decrease in the activation
of the PPRE reporter by relaxin (Fig. 2A), but had no significant
effect on the baseline levels. To determine whether relaxin
causes phosphorylation and activation of p38 MAPK, HEK-
RXFP1 were treated with relaxin for various periods of time,
and phosphorylation of p38 MAPK was monitored (Fig. 2B).
Relaxin caused a rapid and transient increase in p38MAPK
phosphorylation that was maximal between 5 and 15 min, with
a return to baseline levels with increased time. Furthermore,
the relaxin-induced p38 MAPK activation was completely
blocked by treatment with H89 (Fig. 2C), suggesting that p38
MAPK is activated downstream of PKA.
CREB Mediates Relaxin-induced PPAR Activity—A common
downstream target of both PKA and p38MAPK activation is
cAMP response element-binding protein (CREB). Relaxin
treatment of HEK-RXFP1 cells stimulated CREB transcrip-
tional activity of HEK-RXFP1 cells transfected with a CREB
luciferase reporter (Fig. 3A). Furthermore, overexpression of
the dominant-negative CREB (KCREB) resulted in a complete
loss of relaxin-induced PPRE activation (Fig. 3B). Treatment
with relaxin resulted in phosphorylation of CREB at Ser-133
(Fig. 3C). The phosphorylation of CREB in response to relaxin
was completely blocked by a PKA inhibitor, and partially
blocked by the p38 MAPK inhibitor. The partial reduction by
the p38 MAPK inhibitor of CREB phosphorylation (36.0 
2.1%) compares favorably with the decrease in relaxin-stimu-
lated PPRE activity (47.4  2.7%, Fig. 2A). Together, these data
suggest that relaxin causes activation of CREB downstream of
PKA and p38 MAPK.
PGC1 Is the Mechanism for Activation of PPAR Activity by
Relaxin—We have shown earlier that relaxin activation of
PPAR in HEK-RXFP1 cells occurs by a ligand-independent
mechanism (12). The PPAR coactivator PGC1 is capable of
activating PPAR in the absence of PPAR ligand, and further-
more is regulated by both cAMP/PKA and p38 MAPK in a
number of cells (29, 30). Therefore, the effect of relaxin on the
expression level of PGC1 was tested. Relaxin increased the
RNA expression level of PGC1 in HEK-RXFP1 cells (Fig. 4A).
The increased RNA expression was evident by 2 h of treatment,
and started decreasing by 4 h. This increase in expression level
FIGURE 2. p38 MAPK is a downstream mediator of PKA-induced PPAR activity. A, HEK-RXFP1 cells transfected with PPRE and Renilla luciferase reporters
were pretreated 30 min with the p38 MAPK inhibitor PD169316 (20 M) or vehicle, then treated for 24 h with or without 1 nM relaxin then subject to PPRE
luciferase assay. The data are expressed as the PPRE luciferase activity relative to untreated cells, mean  S.E., n  3. *, p  0.05; **, p  0.01. B, HEK-RXFP1 cells
were treated with 1 nM relaxin for the indicated times, and lysates were analyzed by Western blot for total and phosphorylated p38 MAPK. C, cells were
pretreated 30 min with 20 M H89 or vehicle, then treated with 1 nM relaxin for 15 min, and lysates were analyzed by Western blot for total and phosphorylated
p38 MAPK. D, HEK-RXFP1 cells were cotransfected with p38 MAPK siRNA or nontargeting control siRNA and PPRE and Renilla luciferase reporters, then treated
with relaxin as described above, then subject to dual luciferase assay. *, p  .05; ***, p  .001, n  3. E, cells were cotransfected with PKA siRNA or nontargeting
control siRNA, then treated with relaxin for 15 min before Western blot analysis for phosphorylated and total p38 MAPK.
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was mirrored in cells expressing a reporter containing the
PGC1 promoter upstream of luciferase (Fig. 4B). We also
examined the PGC1 protein level, and found that relaxin
caused an increase in PGC1 protein by 4.5 h of treatment (Fig.
4C). The increased expression of PGC1 by relaxin was dimin-
ished by the PKA inhibitor H89 (Fig. 4D). Furthermore, coex-
pression of the dominant-negative KCREB construct decreased
the relaxin-stimulated increase in PGC1 protein levels (Fig.
4E). The involvement of PGC1 in the ability of relaxin to stim-
ulate PPAR activation was examined using siRNA-mediated
knockdown of PGC1 (Fig. 4, F and G). The PGC1-siRNA
reduced the stimulation of PPAR activity by relaxin, while
control siRNA had no effect, suggesting that PGC1 mediates
the effect of relaxin on PPAR. Overall, these results suggest
that relaxin increases PGC1 expression through PKA and
CREB activation.
Relaxin Regulates PGC1 in Cells Endogenously Expressing
RXFP1—The signaling pathways activated by relaxin in HEK-
RXFP1 cells were tested in cells naturally expressing RXFP1. In
the liver, the myofibroblastic hepatic stellate cells are the pre-
dominant RXFP1-expressing cells (31, 32). A human hepatic
stellate cell line (LX2) that recapitulates many of the properties
of activated hepatic stellate cells (27) was used. Relaxin induced
an increase in cAMP levels (Fig. 5A) and activated PKA (Fig.
5B), confirming that LX2 cells are responsive to relaxin. Expres-
sion of RXFP1 was detected in LX2 cells at a modest level com-
pared with HEK-RXFP1 cells or THP1 monocytes previously
shown to express high levels of RXFP1 (Fig. 5C). Relaxin treat-
ment resulted in an increase in transcription through the PPRE
reporter, consistent with activation of PPAR (Fig. 5D). Similar
to the results using HEK-RXFP1 cells, relaxin stimulated phos-
phorylation of p38 MAPK (Fig. 5E). Furthermore, relaxin stim-
ulated phosphorylation of CREB that was reduced by both H89
and the p38 MAPK inhibitor (Fig. 5F). The degree of reduction
of relaxin-stimulated CREB phosphorylation with by the p38
MAPK inhibitor (38.4  4.8%) compares favorably to the
response seen in HEK-RXFP1 cells. Finally, the expression level
of PGC1 was increased in response to relaxin (Fig. 5G). Taken
together, these results confirm that the signaling pathways
leading to PGC1 expression and PPAR activation are intact
in LX2 cells endogenously expressing RXFP1.
DISCUSSION
We have previously shown that relaxin treatment of HEK-
RXFP1 cells caused increased transcriptional activity of PPAR
(12). This activation did not require addition of an exogenous
PPAR ligand, nor was it inhibited by a PPAR ligand-binding
inhibitor, suggesting a ligand-independent mechanism of acti-
vation. Recently, another study showed relaxin activation of
PPAR in parenchymal brain arterioles, where it regulated
hypertrophic outward remodeling (22). In contrast to activa-
tion of PPAR in HEK-RXFP1 cells, the effect in brain arterioles
appears to be ligand-dependent, suggesting that the mecha-
nisms of relaxin regulation of PPAR are tissue-specific. We
sought to elucidate the mechanisms for the ligand-independent
activation of PPAR in HEK-RXFP1 cells, and in a cell line
naturally expressing RXFP1, the LX2 hepatic stellate cells.
Relaxin binding to RXFP1 activates a number of signal trans-
duction pathways, the most completely studied of which is
through cAMP and PKA. Depending on the cell type, RXFP1
couples to multiple G-proteins to activate these pathways. In a
number of cells, including the stably transfected HEK-RXFP1
cells, and some cells endogenously expressing RXFP1 such as
THP-1 and HeLa cells, RXFP1 alters cAMP levels in a biphasic
manner, initially coupling to Gs to activate adenylyl cyclase to
increase cAMP levels, followed by coupling to Go to decrease
cAMP, followed by a delayed activation of adenylyl cyclase by Gi
coupling and activation of phosphoinositide 3-kinase (PI3K)
and protein kinase-C (PKC). Other cells retain the coupling
to Gs, but do not have the delayed phase of cAMP elevation. We
found that the relaxin effect on PPAR activity was mimicked
by direct adenylyl cyclase activation using forskolin, or by the
specific PKA activator Sp-6-Bnz-cAMPS, and was inhibited by
the PKA inhibitor H89. In contrast, a specific activator of Epac,
another mediator of cAMP in some pathways, had no effect,
suggesting that PKA alone was involved. Both pertussis toxin
and a PI3K inhibitor partially blocked the effect of relaxin, sug-
gesting that the delayed phase of cAMP production mediated
by Go coupling by RXFP1 was at least partially responsible for
relaxin’s effects.
FIGURE 3. CREB mediates relaxin-induced PPAR activity. A, HEK-RXFP1
cells were transfected with CRE and Renilla luciferase reporters. The cells were
treated for 24 h with or without 1 nM relaxin and subjected to dual luciferase
assay. B, HEK-RXFP1 cells were transfected with the dominant- negative CREB
construct (pCMV-KCREB), or empty vector (pCMV), and the PPRE and Renilla
luciferase reporters. The cells were treated for 24 h with or without 1 nM
relaxin and subjected to dual luciferase assay. The data are expressed as the
luciferase activity relative to untreated cells, mean  S.E., n  3. ***, p  0.001
compared with untreated control. C, HEK-RXFP1 cells were pretreated for 30
min with 20 M H89, 20 M PD169316 (PD16), or vehicle, then treated 30 min
in the presence or absence of 1 nM relaxin. Lysates were analyzed by Western
blotting for total and phosphorylated CREB. C, HEK-RXFP1 cells were trans-
fected with PKA, p38 MAPK, or nontargeting siRNA, then were treated 30 min
in the presence or absence of 1 nM relaxin. Lysates were analyzed by Western
blotting for total and phosphorylated CREB.
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Depending on the cell type, other pathways are triggered by
RXFP1, including nitric oxide, ERK1/2 and p38 MAPK (1, 2).
Importantly, all of these pathways have been implicated in the
regulation of PPAR (33–35). In a number of cell types, activa-
tion results in activation of various nitric-oxide synthases to
mediate physiological responses (2, 10, 36). However, in the
present study, activation of PPAR was not stimulated by the
addition of nitric oxide donors, nor was the effect of relaxin
reduced with a nitric-oxide synthase inhibitor, suggesting that
the nitric oxide pathway was not involved in regulation of
PPAR activation. Similarly, ERK1/2 inhibitor had no effect on
relaxin-stimulated PPAR activity, suggesting that this path-
way is not involved in this effect. There have been few studies of
the role of p38 MAPK in mediating relaxin effects. In human
periodontal ligament cells, relaxin regulation of matrix metal-
loproteinase expression was reduced by a p38 MAPK inhibitor
(37), and relaxin potentiated BNP2-mediated p38 MAPK acti-
vation in multipotent mesenchymal cells (38). Relaxin induced
activation of p38 MAPK in vascular smooth muscle cells, but
not HeLa or vascular endothelial cells (39) or renal fibroblasts
(40). In the present study, a p38 MAPK inhibitor partially
blocked relaxin’s effects, and relaxin treatment rapidly and
transiently induced phosphorylation of p38 MAPK, which
returned to baseline by 30 min. Therefore, it is possible that the
earlier studies, which employed a much longer period of treat-
ment (45– 60 min), may have missed the peak of p38 MAPK
phosphorylation in those cells. The phosphorylation of p38
MAPK in HEK-RXFP1 was downstream of PKA, as it was com-
pletely blocked by H89.
A major effector of gene transcription downstream of cAMP/
PKA signaling is CREB. Relaxin treatment of human endome-
trial stromal cells resulted in rapid and transient phosphoryla-
tion of CREB (41). In HEK-293 cells stably expressing RXFP1,
relaxin induced activation of a reporter plasmid through a CRE
response element (42). We found that CREB was phosphory-
lated within 20 –30 min of relaxin treatment, and this effect was
completely inhibited by PKA inhibition. In addition, CREB
phosphorylation was partially blocked by a p38 MAPK inhibi-
FIGURE 4. PGC1 is the mechanism for activation of PPAR activity by relaxin. A, HEK-RXFP1 cells were treated at the indicated times with 1 nM relaxin, and
the mRNA for PGC1 was quantified by real time RT-PCR relative to that of TBP. Data are expressed as fold expression of PGC1 compared with untreated cells.
B, HEK-RXFP1 cells were transfected with PGC1-promoter and Renilla luciferase reporters, treated 24 h with 1 nM relaxin, then subject to dual-luciferase assay.
C, HEK-RXFP1 cells were treated with 1 nM relaxin for the indicated times, and lysates were analyzed by Western blotting PGC1 and GAPDH as indicated. D,
HEK-RXFP1 cells were pretreated 20 M H89 or vehicle, then incubated for 2 h in the presence or absence of 1 nM relaxin. The mRNA for PGC1 was quantified
by real time RT-PCR relative to that of TBP. Data are expressed as fold expression of PGC1 compared with untreated cells. E, HEK-RXFP1 cells were transfected
with KCREB or control plasmid, then cells were treated with 1 nM relaxin for 4.5 h. Lysates were analyzed by Western blotting for PGC1 and GAPDH as indicated.
F and G, HEK-RXFP1 cells were cotransfected with control or PGC1 siRNA, PPRE and Renilla reporter vectors. After 24 h, the levels of PGC1 were reduced as
determined by Western blot (F). Cells were then treated with or without 1 nM relaxin for 24 h and subjected to dual luciferase assay (G). The data are expressed
as the luciferase activity relative to untreated cells, mean  S.E., n  3. *, p  0.05; **, p  0.01.
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tor, suggesting a bifurcation in signaling at PKA, through p38
MAPK and converging at CREB. This concept was further sup-
ported by the use of the dominant negative form of CREB,
which completely inhibited PPRE activation in response to
relaxin.
Previously, we reported that relaxin activation of PPAR was
ligand-independent, but the mechanism was unknown. The
transcriptional activity of PPAR can be regulated by phosphor-
ylation. We found no evidence of altered PPAR phosphory-
lation in response to relaxin (data not shown). Another mech-
anism is by association with coactivator and corepressor
proteins. Of particular interest was PGC1, which was discov-
ered as a coactivator of PPAR in brown adipose tissue, where it
acts to regulate proteins involved in thermogenic program-
ming, such as uncoupling protein-1 (43). PGC1 is capable of
ligand-independent binding and activation of PPAR (44). Fur-
thermore, PKA, p38-MAPK and CREB all participate in activa-
tion of PGC1. In muscle and liver, increased PGC1 expres-
sion was triggered by cAMP/PKA or p38 MAPK activation, and
in many cases, CREB was a found to be a downstream target of
p38 MAPK (25, 45– 49). The expression of PGC1 is regulated
by CREB through a consensus CRE sequence in the PGC1
promoter (25, 45). Therefore, PGC1 was possible mechanism
for ligand-independent activation of PPAR. We found that
PGC1 mRNA and protein were increased in response to
relaxin treatment in HEK-RXFP1 cells. This effect was reduced
by a PKA inhibitor or a dominant-negative form of CREB.
Furthermore, reduction of PGC1 levels with siRNA dimin-
ished the ability of relaxin to stimulate PPAR activity. Taken
together, these data strongly suggest that increased PGC1 is
the mechanism for the ligand-independent activation of
PPAR by relaxin.
As discussed earlier, cells expressing RXFP1 differ in their
signaling properties in response to relaxin, and it is important
to compare results in cells with induced expression (such as
HEK-RXFP1 cells) with cells endogenously expressing RXFP1
(50, 51). We previously showed that primary rat and mouse
hepatic cells expressed RXFP1, and responded to relaxin
FIGURE 5. Relaxin regulates PGC1 in LX2 cells endogenously expressing RXFP1. A, LX2 cells were treated with or without 1 nM relaxin in the presence of
the phosphodiesterase inhibitors IBMX (0.5 mM) and imidazolidone (0.1 mM) for 30 min, then cAMP levels were determined. B, cells were pretreated with 20 M
H89 for 30 min, then treated 30 min with 1 nM relaxin. PKA activity was measured by phosphorylation of a PKA substrate. C, total RNA was extracted from THP1,
HEK-RXFP1, HepG2, and LX2 cells, and subject to RT-PCR for detection of RXFP1 or GAPDH transcripts. D, LX2 cells were transfected with the PPRE and Renilla
luciferase reporters, then treated with or without 1 nM relaxin for 24 h and subjected to dual luciferase assay. The data are expressed as the luciferase activity
relative to untreated cells. E, cells were treated with 1 nM relaxin for the indicated times, then lysates were analyzed by Western blotting for total and
phosphorylated p38 MAPK. F, LX2 cells were pretreated 30 min with 20 M H89, 20 M PD169316 (PD16), or vehicle, then treated with or without 1 nM relaxin
for 30 min. Lysates were analyzed by Western blotting for total and phosphorylated CREB. G, LX2 cells were treated with 1 nM relaxin for 2 h, and the mRNA for
PGC1 was quantified by real time RT-PCR relative to that of TBP. Data are expressed as fold expression of PGC1 compared with untreated cells. Mean  S.E.,
n  3. **, p  .01; ***, p  .001.
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(31, 52). In this study, we used LX2 cells, a human hepatic stel-
late cell line that recapitulates many of the properties of pri-
mary cells (27). Relaxin treatment caused an elevation of cAMP
and activation of PKA, and RXFP1 mRNA was detected in LX2
cells, confirming that RXFP1 is expressed and active in these
cells. Relaxin also activated transcription through the PPRE
reporter vector. Both p38-MAPK and CREB were phosphory-
lated in response to relaxin, and CREB phosphorylation was
reduced completely by a PKA inhibitor and partially by a p38-
MAPK inhibitor. Finally, PGC1 expression was increased by
relaxin treatment of LX2 cells. These data suggest that the
RXFP1 signaling pathways leading to PGC1 expression are
similar in both HEK-RXFP1 and LX2 cells.
In summary, we have provided the first evidence of ligand-
independent activation of PPAR by relaxin. The overall
scheme is shown in Fig. 6. Relaxin activates RXFP1 which stim-
ulates cAMP through PI3K-dependent and independent path-
ways to generation to activate PKA. This leads to phosphoryla-
tion of CREB, directly via PKA and indirectly by p38-MAPK.
Activation of CREB leads to expression of PGC1, which asso-
ciates with PPAR to increase its transcriptional activity. It is
important to note that PGC1 is also phosphorylated by a num-
ber of kinases, including PKA and p38-MAPK, to regulate tran-
scriptional activity and protein stability (29, 30). Therefore,
although we found that PGC1 gene expression was up-regu-
lated in response to relaxin, we cannot rule out a role for PGC1
phosphorylation in mediating relaxin’s effects. Nevertheless,
these studies provide the first evidence of PGC1 as a target of
relaxin signaling, and provide the mechanism for the ligand-
independent activation of PPAR by relaxin.
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